Core Viewpoint - Pomerantz LLP is investigating claims of potential securities fraud and unlawful business practices involving New Era Energy & Digital, Inc. and its executives [1] Group 1: Stock Performance and Market Reaction - On December 12, 2025, New Era's stock price fell significantly after a short report by Fuzzy Panda Research accused the company of spending 2.5 times more on stock promotions than on operating its oil and gas wells, leading to a decline of $0.25 per share, or 6.9%, closing at $3.35 [2][3] - Following a lawsuit filed by the state of New Mexico alleging fraudulent activities related to oil and gas operations, New Era's stock price dropped by $2.19 per share, or 48.03%, closing at $2.37 on December 29, 2025 [4] Group 2: Allegations and Legal Actions - The short report from Fuzzy Panda claimed that New Era's CEO, E. Will Gray II, has a history of mismanaging penny stock companies over the past 20 years [2] - The lawsuit from New Mexico accused New Era and its CEO of orchestrating a fraudulent scheme that left the state responsible for significant cleanup costs associated with abandoned wells [4]

Core Viewpoint - The Gross Law Firm is notifying shareholders of SLM Corporation regarding a class action lawsuit due to allegations of misleading statements and undisclosed information related to the company's financial stability and loan delinquency rates during a specified period [1]. Group 1: Allegations and Class Period - The class period for the allegations against SLM Corporation is from July 25, 2025, to August 14, 2025 [1]. - Allegations include that SLM experienced a significant increase in early-stage delinquencies, which was not disclosed, leading to an overstatement of the effectiveness of its loss mitigation and loan modification programs [1]. - The complaint asserts that the defendants' public statements created a materially false and misleading impression regarding SLM's business operations and prospects [1]. Group 2: Shareholder Actions and Deadlines - Shareholders who purchased SLM shares during the class period are encouraged to register for the class action, with a deadline of February 17, 2026, to seek lead plaintiff status [2]. - Once registered, shareholders will be enrolled in a portfolio monitoring software to receive updates on the case's progress [2]. - Participation in the case incurs no cost or obligation for the shareholders [2]. Group 3: Law Firm's Mission and Commitment - The Gross Law Firm is a nationally recognized class action law firm dedicated to protecting investors' rights against deceit and illegal business practices [3]. - The firm aims to ensure companies adhere to responsible business practices and seeks recovery for investors who suffered losses due to misleading statements or omissions [3].

Core Viewpoint - A class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1]. Group 1: Lawsuit Details - The lawsuit is based on claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934, representing investors in Alexandria Real Estate securities [3]. - Investors have until January 26, 2026, to request to lead the case, which is pending in the U.S. District Court for the Central District of California [3]. Group 2: Company Background - Alexandria Real Estate is a real estate investment trust focused on tenants in life science industries, including pharmaceutical and biotechnology companies [4]. Group 3: Financial Performance and Stock Impact - Alexandria Real Estate reported lower-than-expected results for Q3 2025, leading to a stock price drop of $14.93 per share, or over 19%, from $77.87 to $62.94 on October 27-28, 2025 [6]. - The company announced a real estate impairment charge of $323.9 million, with $206 million attributed to its Long Island City property, which was deemed not suitable for life science scaling [5][6].

Core Viewpoint - Fermi Inc. is facing a class action lawsuit due to alleged misleading statements and failure to disclose material facts regarding its business operations and prospects, particularly related to its Project Matador AI campus [5]. Group 1: Company Overview - Fermi Inc. conducted its initial public offering (IPO) on October 1, 2025, selling 37,375,000 shares at a price of $21.00 per share [2]. - Following the IPO, Fermi's stock price has significantly declined, trading as low as $8.59 per share, representing a 59% decrease from the IPO price [4]. Group 2: Key Events - On December 12, 2025, Fermi announced that the first tenant for its Project Matador AI campus had terminated a $150 million funding agreement, leading to a stock price drop of $5.16 per share, or 33.8%, closing at $10.09 [3]. - The lawsuit alleges that Fermi overstated tenant demand for the Project Matador campus and failed to disclose the reliance on a single tenant's funding commitment, which posed a significant risk to the project's financing [5]. Group 3: Legal Action - Investors who purchased Fermi securities during the class period (October 1, 2025, to December 11, 2025) have until March 6, 2026, to file a lead plaintiff motion in the class action lawsuit [1][6].

Core Viewpoint - The U.S. Attorney's Office for the District of New Jersey has filed criminal charges against six individuals for securities fraud, insider trading, and conspiracy, with allegations stemming from insider information related to merger and acquisition deals [1] Group 1: Allegations and Charges - The SEC alleges that between June 2020 and February 2024, an investment banker named Kim provided insider information to Saad Shoukat regarding nine potential merger and acquisition deals [1] - Saad Shoukat allegedly shared this insider information with his brothers, Khan and Okonkwo, leading to illicit trading profits of approximately US$41 million [2] Group 2: Manipulation of Securities - The Shoukat brothers are accused of manipulating the securities of Olema Pharmaceuticals Inc. and Opiant Pharmaceuticals Inc. [2] - In the Olema case, Saad and Arham Shoukat allegedly impersonated doctors to obtain confidential information about clinical trials and published false positive results to inflate the stock price [3] - They profited from trading Olema's stock before the misinformation was corrected, benefiting from the temporarily inflated stock price [4] Group 3: False Press Releases - In a separate scheme, the Shoukat brothers purchased Opiant stock based on insider information from Kim, which indicated that Opiant was a takeover target [5] - When the anticipated deal did not occur, the brothers allegedly issued a false press release about a fictitious partnership to artificially boost Opiant's stock price, allowing them to sell at a higher price [5] Group 4: Regulatory Actions - The SEC is seeking permanent injunctive relief, disgorgement of ill-gotten gains with interest, and civil penalties against the six individuals involved, along with a permanent prohibition against Kim [6]

New York, New York--(Newsfile Corp. - January 7, 2026) - Leading international securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Alexandria Real Estate Equities, Inc. (NYSE: ARE) and certain of the Company's senior executives for securities fraud after a significant stock drop resulting from the potential violations of the federal securities laws. If you invested in Alexandria Real Estate, you are encouraged to obtain additional information by visit ...

Core Viewpoint - Grabar Law Office is investigating claims on behalf of shareholders of CarMax, Inc. regarding potential breaches of fiduciary duties by certain officers and directors [1] Group 1: Investigation Details - The investigation focuses on whether CarMax's officers and directors made false or misleading statements about the company's growth prospects [3] - Allegations include that CarMax overstated its growth due to temporary benefits from customer behavior influenced by speculation regarding tariffs [3] Group 2: Shareholder Actions - Shareholders who purchased CarMax shares prior to June 20, 2025, and still hold them can seek corporate reforms and the return of funds at no cost [2][4] - Interested shareholders are encouraged to contact Grabar Law Office for more information on the investigation and potential actions [2][4]

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Perrigo Company plc securities between February 27, 2023, and November 4, 2025, of the January 16, 2026, deadline to become a lead plaintiff in a class action lawsuit [1] Group 1: Class Action Details - Investors who purchased Perrigo securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1] - A class action lawsuit has already been filed, and interested parties must move the Court by January 16, 2026, to serve as lead plaintiff [2] - The Rosen Law Firm emphasizes the importance of selecting qualified counsel with a successful track record in securities class actions [3] Group 2: Allegations Against Perrigo - The lawsuit alleges that Perrigo made materially false and misleading statements regarding its infant formula business acquired from Nestlé, which suffered from significant underinvestment in maintenance [4] - It is claimed that Perrigo needed to make substantial capital and operational expenditures beyond its stated cost estimates to remediate the infant formula business [4] - The lawsuit also states that there were significant manufacturing deficiencies in the facility for Perrigo's infant formula business, leading to overstated financial results, including earnings and cash flow [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Galectin Therapeutics Inc. and its officers and directors [1] Group 1: Company Developments - On December 19, 2025, Galectin announced that the FDA provided a written response to its Type C meeting request regarding the development program for belapectin, an investigational galectin-3 inhibitor [3] - The FDA's response converted the initial request for an in-person or teleconference meeting to a written format, indicating that key aspects of the trial design remain unresolved despite alignment on the proposed patient population for a registration trial [3] Group 2: Market Reaction - Following the news of the FDA's response, Galectin's stock price fell by $1.78 per share, or 28.9%, closing at $4.38 per share on December 19, 2025 [4]

NEW YORK, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of New Era Energy & Digital, Inc. (“New Era” or the “Company”) (NASDAQ: NUAI). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether New Era and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On ...